06 Aug 2015 --- Novozymes has reported that sales in the first half of 2015 grew by 5% organically and by 15% in DKK compared with 1H 2014. EBIT grew by 12%, and the EBIT margin was 27.2%. Adjusting for the one-time impact from The BioAg Alliance in Q1 2014, EBIT grew by ~20%, and the EBIT margin expanded by ~1 percentage point compared with 1H 2014. The EBIT margin improvement was mainly due to currencies and operational efficiencies. Net profit grew by 8%, and free cash flow before acquisitions came in at DKK 1,616 million (EUR217 million).
